Introduction {#S0001}
============

Breast cancer is the most prevalent female malignancy.[@CIT0001] Despite significant progress in the diagnosis and treatment of breast cancer, the mortality of patients with advanced breast cancer remains high, being mainly attributed to frequent metastasis and recurrence.[@CIT0002],[@CIT0003]

Long noncoding RNAs (lncRNAs) are defined as transcribed RNA molecules of more than 200 nucleotides with no protein-coding capacity and account for the majority of the transcribed genome.[@CIT0004] LncRNAs have been increasingly recognized as key players in cancer development and progression through regulation of cell proliferation, survival, metastasis, senescence, self-renewal, stem cell pluripotency and drug resistance.[@CIT0005],[@CIT0006],[@CIT0007],[@CIT0008],[@CIT0009],[@CIT0010] Recent studies have demonstrated that lncRNAs function by binding to specific target DNA, RNA and/or protein.[@CIT0011] Nevertheless, the clinical relevance and underlying mechanisms of lncRNAs have not been fully understood in breast cancer. Linc00460 (ID in NCBI database: 728192), a newly identified lncRNA, was reported to be dysregulated in various cancer types, including parapharyngeal schwannoma, renal cell carcinoma, head and neck squamous cell carcinoma and breast cancer.[@CIT0012],[@CIT0013],[@CIT0014] Repression of Linc00460 significantly inhibited the proliferation of esophageal and nasopharyngeal carcinoma cells.[@CIT0015],[@CIT0016] Furthermore, several cancer-related transcriptional factors, such as MYC, FOS, CTCF and JUN, have been suggested to regulate the expression level of Linc00460.[@CIT0017] Therefore, we sought to investigate the functional role of Linc00460 in breast cancer.

In the present study, we observed the increased expression of Linc00460 in breast cancer compared to the benign breast tissues. Moreover, Linc00460 expression in the breast cancer cohort was associated with lymph node metastasis and worse survival outcome. Linc00460 depletion decreased breast cancer cell proliferation, migration and invasion, and inhibited tumor growth and lung metastasis in vivo. Mechanistically, our study suggests that Linc00460 sponges endogenous miRNA-489-5p to activate FGF7-AKT signaling, thereby promoting breast cancer progression.

Materials and methods {#S0002}
=====================

Breast cancer specimens and cell lines {#S0002-S2001}
--------------------------------------

Forty-two breast cancer tissues and 15 benign mammary tissues were collected from patients who underwent surgery at the First Affiliated Hospital of Anhui Medical University (Hefei, Anhui, People's Republic of China) between 2009 and 2010. Specimens were transported in liquid nitrogen and stored at --80°C until used. The inclusion criteria were as follows: patients had no history of prior therapy with anticancer drugs or radiotherapy; clinical information of each patient including age, tumor size, tumor stage and lymphatic metastasis was available and written informed consent was obtained from all patients. The study protocol regarding the use of clinical samples was reviewed and approved by the Biomedical Ethics Committee of Anhui Medical University and conducted in accordance with the Declaration of Helsinki. Data from GSE20711 and GSE6532 in the GEO database were extracted to analyze the expression patterns of Linc00460 and FGF7 in the breast cancer tissues. Breast cancer cell lines (MCF-7, BT-474, MDA-MB-231 and BT-549) and a mammary epithelial cell line (MCF-10A) used in this study were purchased from the American Type Culture Collection (Rockville, MD, USA). HMEC-hTERT cells were a gift of Prof. William Hahn, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America. SUM159 and SUM149 cells were obtained from Asterand.[@CIT0018] Cell lines used in this study have been authenticated. MCF-7 and BT-474 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Gibco) at 37°C with 5% CO~2~. BT-549 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 0.01 mg/mL human recombinant insulin (Sigma) at 37°C with 5% CO~2~. MDA-MB-231 cells were cultured in Leibovitz's15 medium supplemented with 10% fetal bovine serum at 37°C in the absence of CO~2~. SUM159 and SUM149 cells were cultured in Ham F-12 (Invitrogen) supplemented with 5% fetal bovine serum, 5 µg/mL insulin and 1 µg/mL hydrocortisone (Sigma) at 37°C with 5% CO~2.~ Cell culture medium for HMEC-TERT and MCF-10A cells was prepared as previously described.[@CIT0019]

RNA extraction and qRT-PCR analysis {#S0002-S2002}
-----------------------------------

Total RNA was isolated from cells and clinical specimens using Trizol (Invitrogen, Carlsbad, CA) and converted to cDNA using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific Bio) following the manufacturer's instructions. The resulting cDNA samples were analyzed by qPCR prepared using SYBR Premix Ex Taq Kit (Takara) and run on Stratagene Mx3000P (Agilent Technology). The expression levels of mRNAs and miRNAs were normalized to the expression level of *GAPDH* and *U6 snRNA,* respectively. The sequences of primers used are listed in [Table S1](#ST0001).

Lentivirus production and stable cell line construction {#S0002-S2003}
-------------------------------------------------------

The full-length Linc00460 DNA fragment was cloned and inserted into pSin vector (pSin) according to the manufacturer's instructions. shRNAs targeting Linc00460 were synthesized and cloned into pLKO.1 vector. All primers and shRNA sequences are listed in [Table S1](#ST0001). Lentivirus production and transduction were performed as previously described.[@CIT0020],[@CIT0021] Forty-eight hours after viral transduction, puromycin was used for selection of stably transduced cells.

MTT assays {#S0002-S2004}
----------

Cells were seeded into 96-well plates at 1,000 cells per well 48 hrs after transfection or the indicated treatments. Cells were cultured for 5 days and cell viability was determined using the MTT reagent (Promega). Absorbance at 570 nm was measured after 2 hrs of incubation with the MTT reagent.

Colony formation assays {#S0002-S2005}
-----------------------

Cells were seeded into 6-well plates at 1,000 cells per well 48 hrs after transfection or the indicated treatments. After 10 days of culture, cells were washed with PBS, fixed with 10% formalin and stained with 0.5% crystal violet (Sigma). Representative images were used for the counting of respective colony numbers in each well.

Migration and invasion assays {#S0002-S2006}
-----------------------------

Cells were seeded into the upper chamber of a 24-well transwell insert (8-μm pores, BD Biosciences, San Jose, CA) at 10^5^ cells per well 48 hrs after transfection or the indicated treatments. Complete medium was added into the lower chamber. After 24--48 hrs, the remaining cells in the upper chamber were gently wiped off with a cotton swab. Cells migrated through the pores in the membrane to the lower surface of the chamber were fixed with 90% ethyl alcohol for half an hour and stained with 0.1% crystal violet. Images of the migrated cells were taken in three randomly chosen fields and the number of cells in each field was counted. The protocol of invasion assay is similar to migration except that the upper chambers were precoated with Matrigel (BD Biosciences) which was diluted by the FBS free medium.

Transfection and luciferase reporter assays {#S0002-S2007}
-------------------------------------------

Full-length Linc00460 and 3'UTR of *FGF7* were amplified and cloned separately into psiCHECK-2 vector. Linc00460 with mutated miR-489-5p-binding site (Linc00460-mut) was obtained by using specific primers as stated in [Table S1](#ST0001). 5×10^4^ MDA-MB-231 or MCF-7 cells were seeded into each well of 24-well plates 24 hrs before transfection. miR-489-5p mimics, miR-489-5p inhibitor or the respective scrambled oligonucleotides control was co-transfected with 0.1 µg of empty psiCHECK-2 vector control or psiCHECK-2 vectors containing Linc00460, Linc00460-mut or FGF7 3'UTR into the cells using Lipofectamine 2000 (Invitrogen). Cells were harvested and lysed 48 hrs after transfection, the luciferase activities were determined by Dual-Luciferase^®^ Reporter Assay System (Promega).Table 1Correlation of Linc00460 expression with clinicopathological features in 42 breast cancer patientsExpression of Linc00460ParameterLow(%)High(%)*P*-valueAge (years)0.533 ＜558 (44.4%)10 (55.6%) ≥5513 (54.2%)11(45.8%)Tumor size (mm)0.030 ＜2513(68.4%)6 (31.6%) ≥258 (34.8%)15 (65.2%)Tumor stage0.041 Ⅰ9 (75.0%)3 (25.0%) Ⅱ-Ⅳ12 (40.0%)18 (60.0%)ER status0.002 Positive16 (72.3%)6 (27.7%) Negative5 (25.0%)15 (75.0%)PR status0.513 Positive8 (57.1%)6 (42.9%) Negative13 (46.4%)15 (53.6%)HER2 status0.757 Positive9 (47.3%)10 (52.7%) Negative12 (52.2%)11 (47.8%)

Biotin pull-down assay {#S0002-S2008}
----------------------

The detailed protocol was described previously.[@CIT0022] Briefly, sense or antisense biotin-labeled DNA oligomers targeting Linc00460 were incubated with lysates from MCF-7 cells. Streptavidin-coupled agarose beads (Invitrogen) were used to enrich the Linc00460 complex 1 hr after incubation. All steps were performed in RNase-free environment. Sequences of probes against Linc00460 are listed in [Table S1](#ST0001).

Anti-AGO2 RNA immunoprecipitation {#S0002-S2009}
---------------------------------

Anti-AGO2 RNA immunoprecipitation was performed as previously described.[@CIT0023] Briefly, breast cancer cells were lysed and the extract was incubated with anti-AGO2 antibody or anti-IgG (Santa Cruz, CA, USA). Protein G agarose beads (Invitrogen) was used to adhere to the immunoprecipitation product. Beads were washed and subjected to RNA extraction. Purified RNA was analyzed by qRT-PCR.

Protein extraction and Western blot {#S0002-S2010}
-----------------------------------

Total protein from cells was extracted by modified RIPA lysis buffer. Western blot was performed as previously described.[@CIT0024] Protein expression was analyzed by ImageQuant LAS4000 (GE Health). All antibodies used are listed in [Table S2](#ST0002).

Xenograft and histological analyses {#S0002-S2011}
-----------------------------------

The protocol for animal experiments was approved by the Institutional Animal Care and Use Committee and followed the guideline of experimental animal welfare of the Laboratory Animal Ethical Committee at University of Science and Technology of China (USTCACUC1601015). Estradiol pellet (0.18 mg) was subcutaneously implanted into the dorsal skin of 4-week-old nude mice 1 week prior to injection of the MCF-7 cells. For the xenograft study, 5×10^6^ MCF-7 control cells, or MCF-7 cells stably transfected with Linc00460, were mixed 1:1 with Matrigel (BD Biosciences) and injected into the second mammary fat pad of the nude mice (N=6). Tumor growth was determined by measuring the length (L) and width (W). Tumor volume was calculated using the formula Volume (mm^3^) = LW^2^ /2. After the last measurement, mice were sacrificed and tumors were collected, weighted, fixed and subjected to subsequent hematoxylin and eosin (H&E) staining analysis.

For tail vein injection, 2×10^6^ MDA-MB-231 cells, which were stably transfected with Linc00460 shRNAs or empty vector, were injected into female BALB/c nude mice via the tail vein. Mice were sacrificed 2 months later and lungs were surgically resected for H&E staining as previously described.[@CIT0025]

Statistical analysis {#S0002-S2012}
--------------------

All the experiments were repeated at least three times. Student's *t*-test or two-way ANOVA was used to analyze the difference between the two groups; chi-squared test was used to analyze the clinicopathological features of breast cancer patients and the frequency of lung metastases; Pearson correlation analysis was used to analyze the correlation between expressions of two genes; Kaplan--Meier's analysis was used for prognostic analyses; univariate and multivariate Cox proportional hazards regression analyses were used to test for independent prognostic factors. All statistical analyses were performed using GraphPad Prism (San Diego, CA) and SPSS version 20.0 software and *p*\<0.05 was considered as statistically significant.

Result {#S0003}
======

Elevated expression of Linc00460 in breast cancer predicts poor prognosis {#S0003-S2001}
-------------------------------------------------------------------------

To evaluate the role of Linc00460 in breast cancer development and progression, we first assessed Linc00460 expression levels in two mammary epithelial cell lines (HMEC-HERT and MCF-10A) and 6 breast cancer cell lines (MCF-7, BT-474, SUM159, SUM149, MDA-MB-231 and BT-549) by qRT-PCR. The expression levels of Linc00460 were significantly higher in high invasive breast cancer cell lines (SUM159, SUM149, MDA-MB-231 and BT-549) as compared to the less invasive breast cancer cells (MCF-7, BT-474) and the normal mammary epithelial cell lines ([Figure 1A](#F0001){ref-type="fig"}). Next, we analyzed Linc00460 level in 42 breast cancer and 15 normal breast specimens. The expression levels of Linc00460 were found to be significantly elevated in breast cancer compared to the normal breast tissue ([Figure 1B](#F0001){ref-type="fig"}). As indicated in [Table 1](#T0003){ref-type="table"}, further pathological examination demonstrated that higher expression of Linc00460 in breast cancer was correlated with larger tumor size (*P*=0.030) and advanced WHO stage (*P*=0.041). Linc00460 expression level was negatively correlated with ER positivity in breast cancer tissues (*P*=0.002). Notably, among the 42 breast cancer samples studied, 21 specimens obtained from patients with lymphatic metastasis (LN^+^) exhibited elevated levels of Linc00460 as compared to their lymphatic node metastasis-free (LN^−^) counterparts ([Figure 1C](#F0001){ref-type="fig"}). Consistently, increased expression of Linc00460 was observed in breast cancer compared to normal breast tissues in the TCGA BRCA cohorts with 1102 breast cancer tissues and 113 normal breast tissues ([Figure 1D](#F0001){ref-type="fig"}). A positive correlation between Linc00460 expression and lymphatic metastasis was also observed in the GSE20711 dataset ([Figure 1E](#F0001){ref-type="fig"}). Furthermore, patients with a higher expression level of Linc00460 exhibited a shorter overall survival rate. ([Figure 1F](#F0001){ref-type="fig"}). In addition, the prognostic value of Linc00460 was evaluated by univariate and multivariate Cox proportional hazards regression analyses. It was observed that Linc00460 was an independent prognostic factor for worse overall survival (HR =4.763, 95% CI: 1.135--19.985, *P*=0.033; [Table 2](#T0004){ref-type="table"}). Collectively, these data suggest that Linc00460 is upregulated in breast cancer and is associated with a poor survival outcome.Table 2Univariate and multivariate Cox proportional hazards regression analysis of Linc00460 for overall survival in breast cancer patientsVariantsUnivariate analysisMultivariate analysisHR95% CI*P*-valueHR95% CI*P*-valueAge; years (≥55 vs \<55)0.8460.315--2.2740.741Tumor size (\>25 mm\
vs or siz2.0350.706--5.8700.188Tumor stage (Ⅰ vs Ⅱ-Ⅳ)1.1440.369--3.5480.816ER status (positive\
vs negative)0.4510.163--1.2460.124PR status (positive\
vs negative)0.9200.319--2.6480.876HER2 status (positive\
vs negative)1.0450.389--2.8170.931Linc00460 (high vs low)4.1361.393--13.642 **0.011** 4.7631.135--19.985**0.033Notes:** Bold values indicate statistical significance, *P*\<0.05. Figure 1Up-regulated Linc00460 in breast cancer tissues, predicts poorer prognosis. (**A**) qRT-PCR analysis of Linc00460 expression in two normal mammary epithelial cell lines and six breast cancer cell lines. Data are presented as mean ± SD and analyzed using independent samples *t*-test. \*\**P*\<0.01. (**B**) qRT-PCR analysis of Linc00460 expression in 42 breast cancer tissues and 15 benign breast tissues. Data were shown as 2^-ΔCt^ and presented as the median with a range, \**P*\<0.05. (**C**) qRT-PCR analysis of Linc00460 expression in 21 breast cancer tissues with lymphatic node metastasis and 20 lymphatic node metastasis-free breast cancer tissues. Data were shown as 2^-ΔCt^ and presented as median with a range, \**P*\<0.05. (**D**) Expression levels of Linc00460 were analyzed in breast cancer tissues and normal breast tissues in TCGA BRCA cohorts. \*\**P*\<0.01 (**E**) Expression levels of Linc00460 were analyzed in 59 breast cancer tissues with lymphatic node metastasis and 29 lymphatic node metastasis free-breast cancer tissues in GSE20711. \**P*\<0.05 (**F**) Kaplan--Meier's analysis of the correlation between Linc00460 expression and the overall survival of 42 breast cancer patients.

Linc00460 promotes the oncogenicity of breast cancer cells in vitro and in vivo {#S0003-S2002}
-------------------------------------------------------------------------------

We next performed functional analyses of Linc00460 in breast cancer cells. MCF-7 (ER+) and MDA-MB-231 (ER-) carcinoma cells were stably transfected with Linc00460 shRNAs (460-sh1 or 460-sh2), Linc00460 expression plasmid, or their respective vector controls. The expression levels of Linc00460 in these cells were verified by qRT-PCR ([Figure 2A](#F0002){ref-type="fig"} and [B](#F0002){ref-type="fig"}). Depleted Linc00460 expression led to significantly reduced cell proliferation in both MCF-7 and MDA-MB-231 cells as determined by MTT and colony formation assays ([Figure 2C](#F0002){ref-type="fig"} and [D](#F0002){ref-type="fig"}). Conversely, forced expression of Linc00460 exerted opposite effects ([Figure 2E](#F0002){ref-type="fig"} and [F](#F0002){ref-type="fig"}). Furthermore, shRNA-mediated depletion of Linc00460 decreased, while the forced expression of Linc00460 increased, migration and invasion of MCF-7 and MDA-MB-231 cells in transwell assays ([Figure 2G](#F0002){ref-type="fig"}--[J](#F0002){ref-type="fig"}).Figure 2Forced expression of Linc00460 promotes proliferation and metastasis of breast cancer cells both in vitro and in vivo. (**A**) Expression levels of Linc00460 were determined by qRT-PCR in MCF-7 and MDA-MB-231 cells stably transfected with Linc00460 shRNAs (460-sh1 and 460-sh2) or empty vector (Ctr). (**B**) Expression levels of Linc00460 were determined by qRT-PCR in MCF-7 and MDA-MB-231 cells stably transfected with pSin plasmid containing Linc00460 (pSin-460oe) or the empty vector (pSin-vec). (**C**and**E**) Cell viabilities of the respective stably transfected MCF-7 and MDA-MB-231 cells were determined by MTT assay over a period of 5 days. (**D**and**F**) Colony formation of the stably transfected MCF-7 and MDA-MB-231 cells was determined over a period of 10 days. (**G--J**) Transwell assays of the stably transfected MCF-7 and MDA-MB-231 cells. Representative pictures were taken at 100× magnification, and the total number of cells on the bottom surface of transwell were counted and presented as the relative fold changes. In all panels of this figure, the statistical differences were all analyzed using independent samples *t*-test. (K-L) Growth of MCF-7-vec or MCF-7-Linc00460 cells-derived tumors in the orthotopic xenograft models (N=6). Data are presented as mean ± SEM and analyzed using two-way ANOVA. \**P*\<0.05. (**M**) H&E staining of respective MCF-7-vec or MCF-7-Linc00460 cells-derived tumors. Arrow indicates fat pad invasion of MCF-7-Linc00460 cells-derived tumors. Images were taken at 100× magnification. (**N**) H&E staining of lung sections of mice with tail vein injections of MDA-MB-231 cells stably transfected with either Linc00460 shRNAs (460-sh1 and 460-sh2) or empty vector (Ctr). The metastatic nodules were indicated by white arrow. Images were taken at 200× magnification. (**O**) Incidence of lung metastasis in mice of tail vein injection model. χ2 test, \*\**P*\<0.01.

To determine the function of Linc00460 in breast cancer progression in vivo, 5×10^6^ low Linc00460-expressing MCF-7 cells, stably transfected with either the Linc00460 expression plasmid or the empty vector, were injected orthotopically into the second mammary fat pad of female nude mice. Tumors derived from MCF-7 cells with forced expression of Linc00460 grew at a significantly faster rate with resultant mean tumor volume and weight approximately two-fold of those tumors derived from MCF-7-vector cells ([Figure 2K](#F0002){ref-type="fig"} and [L](#F0002){ref-type="fig"}). H&E staining of tumor sections revealed significant local invasion in tumors derived from MCF-7-Linc00460 cells, but not in tumors derived from MCF-7-vector cells ([Figure 2M](#F0002){ref-type="fig"}). To further assess the effect of Linc00460 on breast cancer metastasis, MDA-MB-231 cells transfected with either shRNA targeting Linc00460 or empty vector, were injected via the tail vein of 6-week-old nude mice. Depletion of Linc00460 expression produced a significant reduction in the number and size of lung micrometastases derived from metastatic MDA-MB-231 cells ([Figure 2N](#F0002){ref-type="fig"}). Furthermore, while all mice injected with MDA-MB-231-vector cells exhibited lung metastases (100%), a markedly lower frequency of lung metastases (only 25% and 12.5%) was observed in mice injected with MDA-MB-231-shLinc00460 cells ([Figure 2O](#F0002){ref-type="fig"}).

Linc00460 sponges miR-489-5p in breast cancer cells {#S0003-S2003}
---------------------------------------------------

It has been reported that Linc00460 is abundantly expressed in the cytoplasm, suggestive of the possibility that Linc00460 acts as competitive endogenous RNA (ceRNA) or sponges of miRNAs in breast cancer.[@CIT0015],[@CIT0016] miRNAs may act as regulatory adaptors, through which lncRNAs, pseudogenes and messenger RNAs form regulatory crosstalk networks.[@CIT0026] Therefore, we hypothesized that Linc00460 may be a target of tumor suppressive miRNAs. We therefore searched the list of miRNAs predicted to target Linc00460 using miRcode (http://www.mircode.org/mircode/) and RNAhybrid （https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid）. Eight of the identified predicted miRNAs have been reported to be tumor suppressors, of which three were significantly upregulated as a result of Linc00460 repression (data not shown) and only one of the three (miR-489-5p) was downregulated with forced expression of Linc00460 in breast cancer cells, suggestive that Linc00460 may be a target of miR-489-5p ([Figure 3A](#F0003){ref-type="fig"}[--C](#F0003){ref-type="fig"}). A potential miR-489-5p-binding site was also predicted on Linc00460 ([Figure 3D](#F0003){ref-type="fig"}). To verify the functionality of this binding site, Linc00460 with wild type or mutant miR-489-5p-binding sites were cloned into dual luciferase reporter vector (psiCHECK-2) and co-transfected with miR-489-5p or scrambled oligonucleotides into MCF-7 and MDA-MB-231 cells. Forced expression of miR-489-5p significantly decreased wild-type Linc00460-driven luciferase reporter activity but not that of the mutant Linc00460-driven luciferase reporter activity in both cell lines ([Figure 3E](#F0003){ref-type="fig"}). Furthermore, miR-489-5p, together with Linc00460, were enriched in the pull-down fraction of MCF-7 cells using biotin-conjugated probes against Linc00460 ([Figure 3F](#F0003){ref-type="fig"}). Concordantly, we observed a negative correlation between Linc00460 and miR-489-5p expression in breast cancer tissues by Pearson correlation analysis ([Figure 3G](#F0003){ref-type="fig"}). Additionally, expression levels of miR-489-5p were significantly lower in breast cancer compared to normal breast tissues ([Figure 3H](#F0003){ref-type="fig"}), further confirming that miR-489-5p functions as a tumor suppressor.Figure 3Linc00460 is a direct target of miR-489-5p. (**A**) The schema showing the screening process for potential miRNAs that bind Linc00460. (**B--C**) Expression levels of miR-489-5p in MCF-7 and MDA-MB-231 cells, stably transfected with Linc00460 shRNAs (460-sh1 and 460-sh2), Linc00460-expressing plasmid (pSin-460oe) or their respective empty vectors (Ctr, pSin-vec). Data are presented as mean ± SD, analyzed using independent samples *t*-test. \**P*\<0.05; \*\**P*\<0.01. (**D**) Predicted miR-489-5p-binding site in Linc00460 and sequence of the mutated miR-489-5p-binding site used. (**E**) Luciferase reporter plasmids containing wild type Linc00460, mutant Linc00460, or empty luciferase reporter plasmid, were co-transfected with miR-489-5p mimics or scrambled oligonucleotides negative control into MCF-7 cells and MDA-MB-231 cells. Firefly luciferase reporter activities determined were normalized with Renilla luciferase reporter activities. Data are presented as the mean ± SD, analyzed using independent samples *t*-test. \**P*\<0.05. (**F**) Enrichment of Linc00460 and miR-489-5p in biotin-labeled anti-Linc00460 probes pull-down RNA fraction of MCF-7 cells was determined by qRT-PCR. Data are presented as mean ± SD, analyzed using independent samples *t*-test. \**P*\<0.05; \*\**P*\<0.01. (**G**) Pearson's correlation was performed to analyze the correlations between the expression levels of Linc00460 and miR-489-5p in 42 breast cancer tissues. Data were shown as ΔCt (R= -0.3527, *P*\<0.05). (**H**) qRT-PCR analysis of miR-489-5p expression in 42 breast cancer tissues and 15 non-tumorous breast tissues. Data were shown as 2^-ΔCt^ and presented as median with a range, \**P*\<0.05. (Student's *t*-test).

MiR-489-5p acts as a tumor suppressor in breast cancer {#S0003-S2004}
------------------------------------------------------

To verify the tumor suppressive role of miR-489-5p in breast cancer, MCF-7 and MDA-MB-231 cells were transfected with miR-489-5p mimics, single-strand miR-489-5p inhibitor or the respective scrambled oligonucleotides as the negative control ([Figure 4A](#F0004){ref-type="fig"} and [B](#F0004){ref-type="fig"}) and cell functions determined. MTT assays suggested that the forced expression of miR-489-5p decreased, while inhibition of miR-489-5p increased cell viability ([Figure 4C](#F0004){ref-type="fig"} and [D](#F0004){ref-type="fig"}). A similar result was observed in the colony formation assay ([Figure 4E](#F0004){ref-type="fig"} and [F](#F0004){ref-type="fig"}). Moreover, forced expression of miR-489-5p suppressed, while inhibition of miR-489-5p promoted the migration and invasion of MCF-7 and MDA-MB-231 cells in transwell assays ([Figure 4G](#F0004){ref-type="fig"}--[J](#F0004){ref-type="fig"}).Figure 4MiR-489-5p inhibits breast cancer cell proliferation, migration and invasion. (**A**) Expression levels of miR-489-5p were determined by qRT-PCR in MCF-7 and MDA-MB-231 cells transfected with miR-489-5p mimics or negative control scrambled oligonucleotides (NC). (**B**) Expression levels of miR-489-5p were determined by qRT-PCR in MCF-7 and MDA-MB-231 cells transfected with miR-489-5p inhibitor or negative control scrambled oligonucleotides (NC inhibitor). (**C--D**) Cell viabilities of respective transfected MCF-7 and MDA-MB-231 cells were determined by MTT assay 5 days post-seeding. (**E-F**) Colony formation of transfected MCF-7 and MDA-MB-231 cells over a period of 10 days was determined. (**G--J**) Migration and invasion of transfected MCF-7 and MDA-MB-231 cells were determined by transwell assay. All data are present as mean ± SD from three independent experiments. \**P*\<0.05; \*\**P*\<0.01 (Student's *t*-test).

Linc00460 competes with FGF7 for binding of miR-489-5p {#S0003-S2005}
------------------------------------------------------

We further determined the functional targets of miR-489-5p in breast cancer. *FGF7* was predicted to contain a conserved miR-489-5p-binding site using TargetScan (http://www.targetscan.org/) ([Figure 5A](#F0005){ref-type="fig"}).[@CIT0027] To verify that miR-489-5p targeted *FGF7* mRNA, the 3'UTR of *FGF7* was cloned into the psi-CHECK2 luciferase reporter plasmid and co-transfected with miR-489-5p mimics, miR-489-5p inhibitor or scrambled oligonucleotides into MCF-7 or MDA-MB-231 cells. Forced expression of miR-489-5p inhibited, while miR-489-5p antagonism increased *FGF7* 3'UTR-driven luciferase reporter activity in both MCF-7 and MDA-MB-231 cells ([Figure 5B](#F0005){ref-type="fig"} and [5C](#F0005){ref-type="fig"}). We also examined whether miR-489-5p directly regulated FGF7 expression. Forced expression of miR-489-5p decreased, whereas miR-489-5p inhibition increased the mRNA and protein levels of FGF7 in MCF-7 and MDA-MB-231 cells ([Figure 5D](#F0005){ref-type="fig"} and [E](#F0005){ref-type="fig"}). As both Linc00460 and *FGF7* are direct miR-489-5p targets, we next determined whether they competed for binding to miR-489-5p. Forced expression of Linc00460 increased FGF7 expression, whereas Linc00460 depletion decreased FGF7 expression in MCF-7 cells or MDA-MB-231 cells compared to control ([Figure 5F](#F0005){ref-type="fig"}--[I](#F0005){ref-type="fig"}). Elevated FGF7 expression has been reported to promote AKT signaling[@CIT0028], and we therefore examined AKT activity (phosphorylation) in these cells. We observed that the level of phosphorylated AKT was increased in MCF7 and MDA-MB-231 cells with forced expression of Linc00460 ([Figure 5H](#F0005){ref-type="fig"} and [I](#F0005){ref-type="fig"}). In contrast, phosphorylation of AKT was reduced, consistent with a decrease in FGF7 expression in MCF7 and MDA-MB-231 cells, upon Linc00460 depletion ([Figure 5H](#F0005){ref-type="fig"} and [I](#F0005){ref-type="fig"}). Additionally, analysis of the expression levels of Linc00460 and FGF7 from the GSE6532 dataset showed a significant positive correlation by Pearson correlation analysis ([Figure 5J](#F0005){ref-type="fig"}). We finally performed an anti-AGO2 RNA immunoprecipitation assay and observed Linc00460 overexpression reduced the enrichment of FGF7 mRNA on RISC by miR-489-5p in MCF7 and MDA-MB-231 cells ([Figure 5K](#F0005){ref-type="fig"}--[P](#F0005){ref-type="fig"}). Collectively, miR-489-5p inhibits FGF7-AKT signaling, in a manner that is inversely dependent on Linc00460 expression.Figure 5Linc00460 competitively binds to miR-489-5p to increase FGF7 expression and activates downstream AKT signaling. (**A**) Predicted miR-489-5p-binding site on the 3ʹUTR of FGF7 mRNA. (**B**-**C**) Luciferase reporter plasmids containing FGF-7 3ʹUTR or empty control were co-transfected with miR-489-5p mimics, miR-489-5p inhibitors, or their respective scrambled oligonucleotide control into MCF-7 cells and MDA-MB-231 cells. Firefly luciferase reporter activities determined were normalized with Renilla luciferase reporter activities. Data are presented as mean ± SD, analyzed using independent samples *t*-test. \**P*\<0.05. (**D**--**E**) Protein and mRNA levels of FGF7 in MCF-7 and MDA-MB-231 cells transfected miR-489-5p mimics, miR-489-5p inhibitor, or their respective scrambled oligonucleotide control, were analyzed by Western blot and qRT-PCR, respectively. Data are presented as mean ± SD, analyzed using independent samples *t*-test. \**P*\<0.05. (**F**--**G**) Expression levels of FGF7 in MCF-7 and MDA-MB-231 cells transfected with the Linc00460-expressing plasmid, Linc00460 shRNAs or respective empty vectors were determined by qRT-PCR. Data are presented as mean ± SD, analyzed using independent samples *t*-test. \*\**P*\<0.01. (**H**--**I**) Protein levels of FGF7, and phosphorylated and total-AKT in MCF-7 and MDA-MB-231 cells stably transfected with Linc00460-expressing plasmid, Linc00460 shRNAs or respective empty vectors were determined by Western blot. (**J**) Pearson's correlation was performed to analyze the correlations between the levels of Linc00460 and FGF7 in 87 breast cancer tissues from GSE6532 dataset (R=0.3261, *P*\<0.05). (**K**) AGO2 protein levels of co-immunoprecipitated products were measured by Western blot in MCF-7-pSin-460oe cells or --vector cells. (**L**--**M**) RIP-qRT-PCR assays were used to examine the FGF7 and miR-489-5p levels in associated with AGO2 upon Linc00460 overexpression in MCF-7 cells. Data are present as mean ± SD from three independent experiments. \**P*\<0.05; \*\**P*\<0.01 (Student's *t*-test). (**N**) AGO2 protein levels of co-immunoprecipitated products were measured by Western blot in MDA-MB-231-pSin-460oe cells or --vector cells. (**O**--**P**) RIP-qRT-PCR assays were used to examine FGF7 and miR-489-5p levels in associated with AGO2 after Linc00460 overexpression in MDA-MB-231 cells. Data are present as mean ± SD from three independent experiments. \**P*\<0.05; \*\**P*\<0.01 (Student's *t*-test).

Linc00460 promotes oncogenicity through the miR-489-5p/FGF7/AKT axis {#S0003-S2006}
--------------------------------------------------------------------

The FGF7-AKT axis has been reported to promote breast cancer progression.[@CIT0029],[@CIT0030],[@CIT0031] We therefore sought to determine whether the miR-489-5p/FGF-7/AKT axis mediated linc00460-mediated oncogenic behaviors in breast cancer cells. miR-489-5p mimics or scrambled oligonucleotides were transfected into MCF-7 cells to rescue Linc00460 overexpression reduced expression of miR-489-5p. As expected, forced expression of miR-489-5p abolished the growth, migration and invasion advantage conferred by Linc00460 overexpression in MCF-7 cells, as determined by MTT, colony formation and transwell assays ([Figure 6A](#F0006){ref-type="fig"}--[D](#F0006){ref-type="fig"}). Conversely, miR-489-5p inhibition rescued diminished growth, migration and invasion consequent to Linc00460 depletion in MDA-MB-231 cells ([Figure 6E](#F0006){ref-type="fig"}--[H](#F0006){ref-type="fig"}). Consistently, forced expression of miR-489-5p attenuated the Linc00460-mediated increase in FGF7 expression and AKT phosphorylation in MCF-7 cells ([Figure 6I](#F0006){ref-type="fig"} and [J](#F0006){ref-type="fig"}). In contrast, miR-489-5p inhibition rescued the Linc00460 depletion-mediated decrease in FGF7 expression and AKT phosphorylation in MDA-MB-231 cells ([Figure 6I](#F0006){ref-type="fig"} and [K](#F0006){ref-type="fig"}).Figure 6Abrogation of miR-489-5p/FGF7/AKT axis attenuates tumor-promoting effects of Linc00460. (**A**) MCF-7-pSin-460oe cells or --vector cells were transfected with miR-489-5p mimics or negative control scrambled oligonucleotides (NC), and their cell viabilities were assessed by MTT assay after 5 days. (**B**) Colony formation was determined in MCF-7-pSin-460oe cells or -vector cells transfected with miR-489-5p mimics or negative control scrambled oligonucleotides (NC) after 10 days of culture. (**C--D**) Migration and invasion of MCF-7-pSin-460oe cells or -vector cells transfected with miR-489-5p mimics or negative control scrambled oligonucleotides (NC) were determined by transwell assays. (**E**) MDA-MB-231-sh460 cells or control cells were transfected with miR-489-5p inhibitor or negative control scrambled oligonucleotides (NC inhibitor), and their cell viabilities were assessed by MTT assay after 5 days. (**F**) Colony formation was determined in MDA-MB-231-sh460 cells or control cells transfected with miR-489-5p inhibitor or negative control scrambled oligonucleotides (NC inhibitor) after 10 days of culture. (**G--H**) Migration and invasion of MDA-MB-231-sh460 cells or control cells transfected with miR-489-5p inhibitor or negative control oligonucleotides (NC-inhibitor) were determined by transwell assays. (**I**) Protein levels of FGF7 and phosphorylated and total AKT in MCF-7 cells (pSin-vec+NC,pSin-vec+miR-489-5p, pSin-460oe+NC, pSin-460oe+miR-489-5p) and MDA-MB-231 cells (Ctr+NC-inhi, Ctr+miR-489-5p-inhi, 460-sh2+NC-inhi, 460-sh2+miR-489-5p-inhi) were determined by Western blot. (**J--K**) Expression levels of FGF7 were examined by qRT-PCR in MCF-7 cells (pSin-vec+NC, pSin-vec+miR-489-5p, pSin-460oe+NC, pSin-460oe+miR-489-5p) and MDA-MB-231 cells (Ctr+NC-inhi, Ctr+miR-489-5p-inhi, 460-sh2+NC-inhi, 460-sh2+miR-489-5p-inhi). All data are present as mean ± SD from three independent experiments. \**P*\<0.05; \*\**P*\<0.01 (Student's *t*-test).

We further determined if FGF7 and its downstream signaling mediated the oncogenic functions of Linc00460. Linc00460 overexpressing breast cancer cell lines were transfected with FGF7 siRNAs or negative control. FGF7 depletion suppressed the Linc00460-mediated increase in p-AKT levels to levels similar to that of vector control cells ([Figure 7A](#F0007){ref-type="fig"}--[C](#F0007){ref-type="fig"}). Functionally, MTT and colony formation assays revealed that FGF7 silencing attenuated Linc00460-induced proliferation and/or survival of breast cancer cells to levels similar to that of vector control cells ([Figure 7D](#F0007){ref-type="fig"}--[G](#F0007){ref-type="fig"}). Furthermore, transwell assays showed that FGF7 depletion abrogated Linc00460-enhanced migratory and invasive capacities of breast cancer cells to levels similar to that of vector control cells ([Figure 7H](#F0007){ref-type="fig"}--[K](#F0007){ref-type="fig"}). Thus, FGF7 and its downstream AKT signaling mediate the oncogenic role of Linc00460.Figure 7FGF7 and downstream signaling mediate the oncogenic roles of Linc00460 in breast cancer cells. (**A**) Protein levels of FGF7 and phosphorylated and total AKT in four groups of MCF-7 and MDA-MB-231 cells (pSin-vec+si-NC,pSin-vec+si-FGF7, pSin-460oe+si-NC, pSin-460oe+si-FGF7) were determined by Western blot with β-Actin as input control. (**B--C**) Expression levels of FGF7 were examined by qRT-PCR in four groups of MCF-7 and MDA-MB-231 cells (pSin-vec+si-NC,pSin-vec+si-FGF7, pSin-460oe+si-NC, pSin-460oe+ si-FGF7). GAPDH was used as input control. (**D--E** and **H--I**) MCF-7-pSin-460oe cells or -vector cells were transfected with FGF7 siRNAs (si-FGF7) or negative control scrambled oligonucleotides (si-NC). (**D**) Cell viabilities were assessed by MTT assay after 5 days. (**E**) Colony formation was quantified after 10 days of culture. (**H--I**) Migration and invasion were determined by transwell assays. (F--G and J--K) MDA-MB-231-pSin-460oe cells or -vector cells were transfected with FGF7 siRNAs (si-FGF7) or scrambled oligonucleotides (si-NC) (**F**) Cell viabilities assessed by MTT assay after 5 days. (**G**) Colony formation was quantified after 10 days of culture. (**J--K**) Migration and invasion were determined by transwell assays. All data are present as mean ± SD from three independent experiments. \**P*\<0.05; \*\**P*\<0.01 (Student's *t*-test).

Discussion {#S0004}
==========

In this study, we investigated the expression pattern and clinical relevance of Linc00460 in breast cancer. We observed that Linc00460 was frequently upregulated in breast cancer. Forced expression of Linc00460 promoted viability, migration and invasion of breast cancer cells both in vitro and in vivo. Mechanistically, Linc00460 promoted breast cancer progression by sponging miR-489-5p and functioning as a competing endogenous RNA to *FGF7* mRNA, consequently elevating FGF7 expression and enhancing its downstream AKT signaling.[@CIT0028]

Recent studies have reported that the expression of Linc00460 is deregulated in renal cell carcinoma and head and neck squamous cell carcinoma.[@CIT0013] In addition, Linc00460 has also been reported to contribute to the development and progression of esophageal cancer and nasopharyngeal carcinoma.[@CIT0015],[@CIT0016] However, the underlying mechanism(s) by which Linc00460 promotes oncogenicity is not well delineated. We herein demonstrated that Linc00460 is a direct target of miR-489-5p. miR-489-5p has been reported to impair breast cancer proliferation and invasion by targeting the GSE1 coiled-coil protein.[@CIT0032] Interestingly, miR-489-3p, which originates from the same precursor, has been widely demonstrated to be a tumor suppressor, with functions in colorectal cancer, bladder cancer and osteosarcoma amongst other cancers.[@CIT0033]--[@CIT0035] miR-489-3p has been reported to target histone deacetylase 7 (HDAC7) to suppress tumor growth and invasion in colon cancer.[@CIT0033] It has also been reported that the oncogenic KRAS/NF-kappaB/YY1 axis repressed miR-489-3p expression, leading to pancreatic cancer metastasis.[@CIT0036] In this study, we further investigated the functionality of miR-489-5p. In contrast to Linc00460, miR-489-5p was observed to be dramatically downregulated in breast cancer as compared to benign breast tissues. Functionally, we observed that miR-489-5p significantly inhibited the proliferation, migration and invasion of breast cancer cells, acting as a potent tumor suppressor.

Herein, FGF7 was identified as a target of miR-489-5p, competing with Linc00460 for miR-489-5p binding. FGF7 is a mesenchyme-specific heparin-binding growth factor that binds FGF receptor 2 (FGFR2) to regulate numerous cellular processes.[@CIT0037],[@CIT0038] Signaling pathways activated downstream of FGF7/FGFR2 include RAS-mitogen-activated protein kinase, Phospholipase C-γ, phosphoinositide3-kinase and Janus kinase/signal transducer and activator of transcription.[@CIT0028],[@CIT0039],[@CIT0040] Activation of FGF7/FGFR2 signaling has been reported to contribute to development and progression of gastric cancer, prostate cancer, lung adenocarcinoma and breast cancer.[@CIT0037],[@CIT0041]--[@CIT0043] In the current study, we have demonstrated that increased Linc00460 expression inhibits miR-489-5p-mediated downregulation of FGF7 expression and is accompanied by consequent activation of FGF7-AKT pathway in breast cancer cells, revealing a novel cellular mechanism regulating the FGF7 pathway.

Linc00460 expression has previously been reported to be regulated by several well-known cancer-related transcription factors such as MYC, FOS, CTCF and JUN via bioinformatics prediction.[@CIT0017] Together with the prediction from rVista 2.0 (https://rvista.dcode.org/instr_rVISTA.html), we studied the effect of MYC, SP1, FOS transcription factors on the modulation of Linc00460 expression. However, we did not observe a significant change in the expression level of Linc00460 upon the depletion of these transcription factors. Therefore, the mechanism responsible for the upregulation of Linc00460 in breast cancer remains to be further investigated.

Conclusion {#S0005}
==========

We demonstrated that Linc00460 was increased in expression in breast cancer and that the Linc00460/miR-489-5p/FGF7/AKT axis promoted proliferation, migration and invasion in breast cancer. A higher expression level of Linc00460 was prognostic for a shorter overall survival rate in breast cancer patients. Therefore, Linc00460 is a potential novel diagnostic biomarker for breast cancer prognosis.
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Table S1Oligomers used in this studyNameApplicationSequenceqrt-Linc00460-FqRT-PCRAGAAAGACTGAGCGTGGGAqrt-Linc00460-RqRT-PCRGTCATTTTGGAGGCTGGAAqrt-FGF7-FqRT-PCRCAGTGGCAGTTGGAATqrt- FGF7-RqRT-PCRAGTGGGCTGTTTTTTGqrt-GAPDH-FqRT-PCRTGCACCACCAACTGCTTAGCqrt-GAPDH-RqRT-PCRGGCATGGACTGTGGTCATGAGqrt-miR-489-5p-FqRT-PCRCGGTCGTATGTGTGACGqrt-miR-489-5p-RqRT-PCRGTGCAGGGTCCGAGGTqrt-U6-FqRT-PCRTGCGGGTGCTCGCTTCGGCAGCqrt-U6-RqRT-PCRCCAGTGCAGGGTCCGAGGTU6-RTRTGTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAAATATGGAACmiR-589-5p-RTRTGTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAATGGLinc00460-shRNA1-Fplasmid constructionccggGAGGTACCCAGACATTGTTATggatccATAACAATGTCTGGGTACCTCtttttgLinc00460-shRNA1-Rplasmid constructionaattcaaaaaGAGGTACCCAGACATTGTTATggatccATAACAATGTCTGGGTACCTCLinc00460-shRNA2-Fplasmid constructionccggGGATGAGAACGAAGGTTACGAggatccTCGTAACCTTCGTTCTCATCCtttttgLinc00460-shRNA2-Rplasmid constructionaattcaaaaaGGATGAGAACGAAGGTTACGAggatccTCGTAACCTTCGTTCTCATCCLinc00460-clone-Fplasmid constructionCTAGAATTCACTTCCTGCAGAAATCCTCCAGCCCTLinc00460-clone-Rplasmid constructionCTAGGATCCTAATAATCAGAAATTACTAATTTCTGATTAATAAATTACATTTATTAATCCTGATCATAAAGLinc00460-clone for luci-Fplasmid constructionCTACTCGAGACTTCCTGCAGAAATCCTCCAGCLinc00460-clone for luci-Rplasmid constructionCTAGCGGCCGCTAATAATCAGAAATTACTAATTTCTGATTAATAAATTACATTTATTAATCCTLinc00460mut1-clone for luci-Fplasmid constructionGAGAACGAAGGTGAGGCCGATTGTGTGGGAGGCGTCTGTLinc00460mut1-clone for luci-Rplasmid constructionACAGACGCCTCCCACACAATCGGCCTCACCTTCGTTCTCLinc00460mut2-clone for luci-Fplasmid constructionCCTGGTGGACGGAGGTGCAGCCAGCATGCACACTTCTCGGLinc00460mut2-clone for luci-Rplasmid constructionCCGAGAAGTGTGCATGCTGGCTGCACCTCCGTCCACCAGGFGF7-3ʹUTR-Fplasmid constructionCTACTCGAGTTGCATATGGTATATAAAGAACCAGTTCCAGCAFGF7-3ʹUTR-Rplasmid constructionCTAGCGGCCGCTCTAATTGTTAGAAACTCATGTATTTAATTTTATCLinc00460-DNA-1-senselncRNA pull down（biotin-）GAGGTACCCAGACATTGTTATGAAACTCGLinc00460-DNA-1-antisenselncRNA pull down（biotin-）CGGAGTTTCATAACAATGTCTGGGTACCTCLinc00460-DNA-2-senselncRNA pull down（biotin-）GATGAACCACCATTGCCAGCGGGGAGCAGLinc00460-DNA-2-antisenselncRNA pull down（biotin-）CATGCTCCCCGCTGGCAATGGTGGTTCATCLinc00460-DNA-3-senselncRNA pull down（biotin-）CAAAGTATTCTGTCATAGCTCCCCAAATAGLinc00460-DNA-3-antisenselncRNA pull down（biotin-）CTATTTGGGGAGCTATGACAGAATACTTTGLinc00460-DNA-4-senselncRNA pull down（biotin-）GAGGCGTCTGTGTAGCAATTGCTGGAATCALinc00460-DNA-4-antisenselncRNA pull down（biotin-）TGATTCCAGCAATTGCTACACAGACGCCTCLinc00460-DNA-5-senselncRNA pull down（biotin-）CGATTTATGTTAAATTATCACCTTGACTACLinc00460-DNA-5-antisenselncRNA pull down（biotin-）GTAGTCAAGGTGATAATTTAACATAAATCGLinc00460-DNA-6-senselncRNA pull down（biotin-）ATAAGATAGTATTAATAGATGGGGCCTTTGLinc00460-DNA-6-antisenselncRNA pull down（biotin-）CAAAGGCCCCATCTATTAATACTATCTTATLinc00460-DNA-7-senselncRNA pull down（biotin-）GCCCGAATAAAAGGGGCCCCAGAGAGATCCLinc00460-DNA-7-antisenselncRNA pull down（biotin-）GGATCTCTCTGGGGCCCCTTTTATTCGGGCLinc00460-DNA-8-senselncRNA pull down（biotin-）CTCACCAGAACCCAGTTGTGCTGGCACCCTLinc00460-DNA-8-antisenselncRNA pull down（biotin-）AGGGTGCCAGCACAACTGGGTTCTGGTGAG Table S2Antibodies used in this studyAntibodiesSourceCatalog number*p*-Akt（S473）CST\#9271sAkt1Santa Cruzsc-5298FGF7Abcamab131162β-ACTINProteintech60,008-1-APAGO2Santa Cruzsc-53,521
